Skip to main content
Erschienen in: Cancer Causes & Control 5/2010

01.05.2010 | Original Paper

Parkinson’s disease and cancer risk: a systematic review and meta-analysis

verfasst von: Archna Bajaj, Jane A. Driver, Eva S. Schernhammer

Erschienen in: Cancer Causes & Control | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective

To appraise the existing literature on cancer risk among patients with Parkinson’s disease (PD), determine the overall cancer risk ratio among patients with PD, explore reasons for variations in study results, and assess the potential for publication bias.

Methods

Studies reporting cancer risk in patients with PD were identified by searching electronic databases through 18 November 2009 using the terms PARKINSON DISEASE, NEOPLASM, and CANCER. Reviewers individually performed data extraction and scored each study using a quality assessment instrument. Cancer risk in all patients with PD was calculated overall, and after excluding melanoma and other skin cancers. We tested for heterogeneity and publication bias, and stratified for gender, smoking-related versus non-smoking-related cancers, and study quality. We pooled effect sizes using fixed-effects and random-effects models.

Results

We included 29 studies in the overall analysis for a total of 107,598 patients with PD. Compared to controls, the aggregate risk for cancer in patients with PD was 0.73 (95% confidence interval [CI], 0.63–0.83), and after excluding skin tumors, 0.69 (95% CI, 0.62–0.78). These risks varied by gender (males, RR = 0.71, 95% CI, 0.57–0.88; females, RR = 0.82; 95% CI, 0.68–0.98). After strictly excluding skin tumors, both smoking-related (RR = 0.61; 95% CI, 0.58–0.65) and non-smoking-related cancer rates (RR = 0.76; 95% CI, 0.65–0.89) were significantly lower among patients with PD .

Conclusions

Studies on cancer risk among patients with PD collectively show significantly reduced cancer risk ratios. Further research to explain the biological mechanisms, particularly for the association with non-smoking-related cancers, appears warranted.
Literatur
1.
Zurück zum Zitat Inzelberg R, Jankovic J (2007) Are Parkinson disease patients protected from some but not all cancers? Neurology 69(15):1542–1550CrossRefPubMed Inzelberg R, Jankovic J (2007) Are Parkinson disease patients protected from some but not all cancers? Neurology 69(15):1542–1550CrossRefPubMed
2.
Zurück zum Zitat West AB, Dawson VL, Dawson TM (2005) To die or grow: Parkinson’s disease and cancer. Trends Neurosci 28(7):348–352CrossRefPubMed West AB, Dawson VL, Dawson TM (2005) To die or grow: Parkinson’s disease and cancer. Trends Neurosci 28(7):348–352CrossRefPubMed
3.
Zurück zum Zitat Staropoli JF (2008) Tumorigenesis and neurodegeneration: two sides of the same coin? Bioessays 30(8):719–727CrossRefPubMed Staropoli JF (2008) Tumorigenesis and neurodegeneration: two sides of the same coin? Bioessays 30(8):719–727CrossRefPubMed
4.
Zurück zum Zitat Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T (2007) A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Cancer Epidemiol Biomarkers Prev 16(6):1260–1265CrossRefPubMed Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T (2007) A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Cancer Epidemiol Biomarkers Prev 16(6):1260–1265CrossRefPubMed
5.
Zurück zum Zitat Olsen JH, Friis S, Frederiksen K (2006) Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 17(5):582–587CrossRefPubMed Olsen JH, Friis S, Frederiksen K (2006) Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 17(5):582–587CrossRefPubMed
6.
Zurück zum Zitat Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H (2005) Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer 92(1):201–205CrossRefPubMed Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H (2005) Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer 92(1):201–205CrossRefPubMed
7.
Zurück zum Zitat Vanacore N, Spila-Alegiani S, Raschetti R, Meco G (1999) Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 52(2):395–398PubMed Vanacore N, Spila-Alegiani S, Raschetti R, Meco G (1999) Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 52(2):395–398PubMed
8.
Zurück zum Zitat Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S (2007) Treatment with levodopa and risk for malignant melanoma. Mov Disord 22(9):1252–1257CrossRefPubMed Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S (2007) Treatment with levodopa and risk for malignant melanoma. Mov Disord 22(9):1252–1257CrossRefPubMed
9.
Zurück zum Zitat Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012CrossRefPubMed Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012CrossRefPubMed
10.
Zurück zum Zitat D’Amelio M, Ragonese P, Morgante L, Reggio A, Callari G, Salemi G et al (2006) Long-term survival of Parkinson’s disease. J Neurol 253:33–37CrossRefPubMed D’Amelio M, Ragonese P, Morgante L, Reggio A, Callari G, Salemi G et al (2006) Long-term survival of Parkinson’s disease. J Neurol 253:33–37CrossRefPubMed
11.
Zurück zum Zitat Elbaz A, Peterson BJ, Bower JH, Yang P, Maraganore DM, McDonnell SK et al (2005) Risk of cancer after the diagnosis of Parkinson’s disease: a historical cohort study. Mov Disord 20(6):719–725CrossRefPubMed Elbaz A, Peterson BJ, Bower JH, Yang P, Maraganore DM, McDonnell SK et al (2005) Risk of cancer after the diagnosis of Parkinson’s disease: a historical cohort study. Mov Disord 20(6):719–725CrossRefPubMed
12.
Zurück zum Zitat Leibson CL, Maraganore DM, Bower JH, Ransom JE, O’Brien PC, Rocca WA (2006) Comorbid conditions associated with Parkinson’s disease: a population-based study. Mov Disord 21(4):446–455CrossRefPubMed Leibson CL, Maraganore DM, Bower JH, Ransom JE, O’Brien PC, Rocca WA (2006) Comorbid conditions associated with Parkinson’s disease: a population-based study. Mov Disord 21(4):446–455CrossRefPubMed
13.
Zurück zum Zitat Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH (1995) Occurrence of different cancers in patients with Parkinson’s disease. BMJ 310(6993):1500–1501PubMed Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH (1995) Occurrence of different cancers in patients with Parkinson’s disease. BMJ 310(6993):1500–1501PubMed
14.
Zurück zum Zitat Morgante L (2000) Parkinson disease survival: a population based study. Arch Neurol 57(4):507–512CrossRefPubMed Morgante L (2000) Parkinson disease survival: a population based study. Arch Neurol 57(4):507–512CrossRefPubMed
15.
Zurück zum Zitat Raschetti R, Spila-Alegiani S, Vanacore N, Ancona C, Meco G (1998) Mortality in a population-based cohort of patients treated with antiparkinsonian drugs. Acta Neurol Scand 97(1):20–26PubMed Raschetti R, Spila-Alegiani S, Vanacore N, Ancona C, Meco G (1998) Mortality in a population-based cohort of patients treated with antiparkinsonian drugs. Acta Neurol Scand 97(1):20–26PubMed
16.
Zurück zum Zitat Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G (2007) Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson’s disease. Cancer Causes Control 18(7):705–711CrossRefPubMed Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G (2007) Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson’s disease. Cancer Causes Control 18(7):705–711CrossRefPubMed
17.
Zurück zum Zitat Elbaz A, Peterson BJ, Yang P, Van Gerpen JA, Bower JH, Maraganore DM et al (2002) Nonfatal cancer preceding Parkinson’s disease: a case-control study. Epidemiology 13(2):157–164CrossRefPubMed Elbaz A, Peterson BJ, Yang P, Van Gerpen JA, Bower JH, Maraganore DM et al (2002) Nonfatal cancer preceding Parkinson’s disease: a case-control study. Epidemiology 13(2):157–164CrossRefPubMed
18.
Zurück zum Zitat Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G (2008) Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology 70(16 pt 2):1423–1430CrossRefPubMed Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G (2008) Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology 70(16 pt 2):1423–1430CrossRefPubMed
19.
Zurück zum Zitat Gorell JM, Johnson CC, Rybicki BA (1994) Parkinson’s disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology 44(10):1865–1868PubMed Gorell JM, Johnson CC, Rybicki BA (1994) Parkinson’s disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology 44(10):1865–1868PubMed
20.
Zurück zum Zitat Kondo K (1984) Motor neuron disease and Parkinson’s disease are not associated with other disorders at autopsy. Neuroepidemiology 3:182–194CrossRef Kondo K (1984) Motor neuron disease and Parkinson’s disease are not associated with other disorders at autopsy. Neuroepidemiology 3:182–194CrossRef
21.
Zurück zum Zitat Marmot MG (1981) Mortality and Parkinson’s disease. In: Rose FC, Capildeo R (eds) Research progress in Parkinsons’ disease. Pitman Medical, Kent, pp 9–16 Marmot MG (1981) Mortality and Parkinson’s disease. In: Rose FC, Capildeo R (eds) Research progress in Parkinsons’ disease. Pitman Medical, Kent, pp 9–16
22.
Zurück zum Zitat Pritchard PB III, Netsky MG (1973) Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study. Neurology 23(3):215–222PubMed Pritchard PB III, Netsky MG (1973) Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study. Neurology 23(3):215–222PubMed
23.
Zurück zum Zitat Levine RL, Jones JC, Bee N (1992) Stroke and Parkinson’s disease. Stroke 23(6):839–842PubMed Levine RL, Jones JC, Bee N (1992) Stroke and Parkinson’s disease. Stroke 23(6):839–842PubMed
24.
Zurück zum Zitat Di Rocco A, Molinari SP, Kollmeier B, Yahr MD (1996) Parkinson’s disease: progression and mortality in the l-DOPA era. Adv Neurol 69:3–11PubMed Di Rocco A, Molinari SP, Kollmeier B, Yahr MD (1996) Parkinson’s disease: progression and mortality in the l-DOPA era. Adv Neurol 69:3–11PubMed
25.
Zurück zum Zitat Vital Statistics of the United States, 1963. Hyattsville, MD: Centers for Disease Control and Prevention, National Center for Health Statistics; 1965 Vital Statistics of the United States, 1963. Hyattsville, MD: Centers for Disease Control and Prevention, National Center for Health Statistics; 1965
26.
Zurück zum Zitat The health consequences of smoking: a report of the surgeon general. Atlanta, GA: Centers for Disease Control and Prevention, Office on Smoking and Health; 2004 The health consequences of smoking: a report of the surgeon general. Atlanta, GA: Centers for Disease Control and Prevention, Office on Smoking and Health; 2004
27.
Zurück zum Zitat Walker AM (1991) Observation and inference: an introduction to the methods of epidemiology. Newton Lower Falls, Epidemiology Resources Inc Walker AM (1991) Observation and inference: an introduction to the methods of epidemiology. Newton Lower Falls, Epidemiology Resources Inc
28.
Zurück zum Zitat DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed
29.
Zurück zum Zitat Cochran WG (1954) Some methods for strengthening the common χ2 tests. Biometrics 10(4):417–451CrossRef Cochran WG (1954) Some methods for strengthening the common χ2 tests. Biometrics 10(4):417–451CrossRef
30.
Zurück zum Zitat Takkouche B, Cadarso-Suarez C, Spiegalman D (1999) Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 150:206–215PubMed Takkouche B, Cadarso-Suarez C, Spiegalman D (1999) Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 150:206–215PubMed
31.
Zurück zum Zitat Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefPubMed Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefPubMed
32.
Zurück zum Zitat Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMed Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMed
34.
Zurück zum Zitat Barbeau A, Joly JG (1963) Parkinson et cancer. Union Med Can 92:169–174PubMed Barbeau A, Joly JG (1963) Parkinson et cancer. Union Med Can 92:169–174PubMed
35.
Zurück zum Zitat Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD (2004) Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort. Mov Disord 19(1):49–53CrossRefPubMed Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD (2004) Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort. Mov Disord 19(1):49–53CrossRefPubMed
36.
Zurück zum Zitat Jansson B, Jankovic J (1985) Low cancer rates among patients with Parkinson’s disease. Ann Neurol 17(5):505–509CrossRefPubMed Jansson B, Jankovic J (1985) Low cancer rates among patients with Parkinson’s disease. Ann Neurol 17(5):505–509CrossRefPubMed
37.
Zurück zum Zitat Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S (2000) Mortality and cancer incidence in patients with Parkinson’s disease. J Neurol 247(6):429–434CrossRefPubMed Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S (2000) Mortality and cancer incidence in patients with Parkinson’s disease. J Neurol 247(6):429–434CrossRefPubMed
38.
Zurück zum Zitat Pressley JC, Louis ED, Tang MX, Cote L, Cohen PD, Glied S et al (2003) The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology 60(1):87–93PubMed Pressley JC, Louis ED, Tang MX, Cote L, Cohen PD, Glied S et al (2003) The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology 60(1):87–93PubMed
39.
Zurück zum Zitat Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ (2009) Cancer in patients with motor neuron disease, multiple sclerosis, and Parkinson’s disease: record-linkage studies. J Neurol Neurosurg Psychiatry Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ (2009) Cancer in patients with motor neuron disease, multiple sclerosis, and Parkinson’s disease: record-linkage studies. J Neurol Neurosurg Psychiatry
40.
Zurück zum Zitat D’Amelio M, Ragonese P, Morgante L, Epifanio A, Callari G, Salemi G et al (2004) Tumor diagnosis preceding Parkinson’s disease: a case-control study. Mov Disord 19(7):807–811CrossRefPubMed D’Amelio M, Ragonese P, Morgante L, Epifanio A, Callari G, Salemi G et al (2004) Tumor diagnosis preceding Parkinson’s disease: a case-control study. Mov Disord 19(7):807–811CrossRefPubMed
41.
Zurück zum Zitat Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H (2006) Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Parkinsonism Relat Disord 12(3):185–189CrossRefPubMed Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H (2006) Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Parkinsonism Relat Disord 12(3):185–189CrossRefPubMed
42.
Zurück zum Zitat Rajput AH, Offord KP, Beard CM, Kurland LT (1987) A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson’s disease. Neurology 37(2):226–232PubMed Rajput AH, Offord KP, Beard CM, Kurland LT (1987) A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson’s disease. Neurology 37(2):226–232PubMed
43.
Zurück zum Zitat Ben-Shlomo Y, Marmot MG (1995) Survival and cause of death in a cohort of patients with Parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58(3):293–299CrossRefPubMed Ben-Shlomo Y, Marmot MG (1995) Survival and cause of death in a cohort of patients with Parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58(3):293–299CrossRefPubMed
44.
Zurück zum Zitat Beyer MK, Herlofson K, Arsland D, Larsen JP (2001) Causes of death in a community-based study of Parkinson’s disease. Acta Neurol Scand 103(1):7–11CrossRefPubMed Beyer MK, Herlofson K, Arsland D, Larsen JP (2001) Causes of death in a community-based study of Parkinson’s disease. Acta Neurol Scand 103(1):7–11CrossRefPubMed
45.
Zurück zum Zitat Fall PA, Saleh A, Fredrickson M, Olsson JE, Granerus AK (2003) Survival time, mortality, and cause of death in elderly patients with Parkinson’s disease: a 9-year follow-up. Mov Disord 18(11):1312–1316CrossRefPubMed Fall PA, Saleh A, Fredrickson M, Olsson JE, Granerus AK (2003) Survival time, mortality, and cause of death in elderly patients with Parkinson’s disease: a 9-year follow-up. Mov Disord 18(11):1312–1316CrossRefPubMed
46.
Zurück zum Zitat Harada H, Nishikawa S, Takahashi K (1983) Epidemiology of Parkinson’s disease in a Japanese city. Arch Neurol 40(3):151–154PubMed Harada H, Nishikawa S, Takahashi K (1983) Epidemiology of Parkinson’s disease in a Japanese city. Arch Neurol 40(3):151–154PubMed
47.
Zurück zum Zitat Hely MA, Morris JG, Traficante R, Reid WG, O’Sullivan DJ, Williamson PM (1999) The Sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 67(3):300–307CrossRefPubMed Hely MA, Morris JG, Traficante R, Reid WG, O’Sullivan DJ, Williamson PM (1999) The Sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 67(3):300–307CrossRefPubMed
48.
Zurück zum Zitat Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442PubMed Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442PubMed
49.
Zurück zum Zitat Kessler II (1972) Epidemiologic studies of Parkinson’s disease. II. A hospital-based survey. Am J Epidemiol 95(4):308–318PubMed Kessler II (1972) Epidemiologic studies of Parkinson’s disease. II. A hospital-based survey. Am J Epidemiol 95(4):308–318PubMed
50.
Zurück zum Zitat Louis ED, Marder K, Cote L, Tang M, Mayeux R (1997) Mortality from Parkinson’s disease. Arch Neurol 54(3):260–264PubMed Louis ED, Marder K, Cote L, Tang M, Mayeux R (1997) Mortality from Parkinson’s disease. Arch Neurol 54(3):260–264PubMed
51.
Zurück zum Zitat Wermuth L, Stenager EN, Stenager E, Boldsen J (1995) Mortality in patients with Parkinson’s disease. Acta Neurol Scand 92(1):55–58PubMedCrossRef Wermuth L, Stenager EN, Stenager E, Boldsen J (1995) Mortality in patients with Parkinson’s disease. Acta Neurol Scand 92(1):55–58PubMedCrossRef
52.
Zurück zum Zitat Westlund K, Hougen A (1956) Cancer as a cause of death among patients with other chronic diseases. J Am Med Assoc 162:1003 Westlund K, Hougen A (1956) Cancer as a cause of death among patients with other chronic diseases. J Am Med Assoc 162:1003
54.
Zurück zum Zitat Riggs JE (1999) Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 53(5):1158–1159PubMed Riggs JE (1999) Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 53(5):1158–1159PubMed
55.
Zurück zum Zitat Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 52:276–284CrossRefPubMed Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 52:276–284CrossRefPubMed
56.
Zurück zum Zitat McNaught KS, Perl DP, Brownell AL, Olanow CW (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann Neurol 56(1):149–162CrossRefPubMed McNaught KS, Perl DP, Brownell AL, Olanow CW (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann Neurol 56(1):149–162CrossRefPubMed
57.
Zurück zum Zitat Montagut C, Rovira A, Albanell J (2006) The proteasome: a novel target for anticancer therapy. Clin Transl Oncol 8(5):313–317CrossRefPubMed Montagut C, Rovira A, Albanell J (2006) The proteasome: a novel target for anticancer therapy. Clin Transl Oncol 8(5):313–317CrossRefPubMed
58.
Zurück zum Zitat Schernhammer E, Chen H, Ritz B (2006) Circulating melatonin levels: possible link between Parkinson’s disease and cancer risk? Cancer Causes Control 17(4):577–582CrossRefPubMed Schernhammer E, Chen H, Ritz B (2006) Circulating melatonin levels: possible link between Parkinson’s disease and cancer risk? Cancer Causes Control 17(4):577–582CrossRefPubMed
59.
Zurück zum Zitat Zanetti R, Loria D, Rosso S (2006) Melanoma, Parkinson’s disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res 16(3):201–206CrossRefPubMed Zanetti R, Loria D, Rosso S (2006) Melanoma, Parkinson’s disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res 16(3):201–206CrossRefPubMed
60.
Zurück zum Zitat Fiala KH, Whetteckey J, Manyam BV (2003) Malignant melanoma and levodopa in Parkinson’s disease: causality or coincidence? Parkinsonism Relat Disord 9(6):321–327CrossRefPubMed Fiala KH, Whetteckey J, Manyam BV (2003) Malignant melanoma and levodopa in Parkinson’s disease: causality or coincidence? Parkinsonism Relat Disord 9(6):321–327CrossRefPubMed
Metadaten
Titel
Parkinson’s disease and cancer risk: a systematic review and meta-analysis
verfasst von
Archna Bajaj
Jane A. Driver
Eva S. Schernhammer
Publikationsdatum
01.05.2010
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 5/2010
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-009-9497-6

Weitere Artikel der Ausgabe 5/2010

Cancer Causes & Control 5/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.